Literature DB >> 30679106

Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.

Satyam Arora1, Navneet S Majhail2, Hien Liu3.   

Abstract

Successful stem cell mobilization and adequate harvesting of hematopoietic progenitor cells (HPCs) is necessary for patients with multiple myeloma (MM) undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT). Several advances have increased the efficiency and yield of HPC collection methods, and sufficient CD34+ cell collection can be expected for most patients with MM considered to be ASCT candidates. However, in some patients, HPCs will fail to mobilize and an adequate number of CD34+ cells will not be collected. In our review, we have discussed the various strategies available for mobilizing HPCs in patients with MM and the evolution of these strategies over time. We have also discussed the concept of mobilization failure, the factors predictive of poor mobilization, and the potential mobilization regimens for such patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD34(+); G-CSF; HPC mobilization; Mobilization; Plerixafor

Mesh:

Substances:

Year:  2018        PMID: 30679106     DOI: 10.1016/j.clml.2018.12.010

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  7 in total

1.  Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma.

Authors:  Neerja Kushwaha; Sudeep Kumar; Mohd Anas Sheikh; Joseph Philip; Sanjeevan Sharma; Amit Kumar Biswas; Rajneesh Kumar Joshi
Journal:  Med J Armed Forces India       Date:  2021-03-24

Review 2.  Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.

Authors:  Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel
Journal:  Curr Treat Options Neurol       Date:  2019-10-17       Impact factor: 3.598

3.  Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.

Authors:  Liwen Wang; Hongxian Xiang; Yuhan Yan; Zuqun Deng; Hui Li; Xin Li; Jin Liu
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

Review 4.  Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Authors:  Grace Lassiter; Cole Bergeron; Ryan Guedry; Julia Cucarola; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Curr Oncol       Date:  2021-01-21       Impact factor: 3.677

Review 5.  Cell-based immunotherapy of glioblastoma multiforme.

Authors:  Igor Bryukhovetskiy
Journal:  Oncol Lett       Date:  2022-02-23       Impact factor: 2.967

6.  [Activity report of the Bone Marrow Transplant Department of the Mohammed VI University Hospital, Marrakech, Morocco, over the period 2012- 2018].

Authors:  Mehdi Loukhnati; Fatima Ezzahra Lahlimi; Illias Tazi
Journal:  Pan Afr Med J       Date:  2021-07-06

7.  High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma.

Authors:  Zhijuan Zhu; Xiaofan Li; Yiping Liu; Ping Chen; Xianling Chen; Hua Li; Jiafu Huang; Yuanzhong Chen; Nainong Li
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.